CvergenX to develop radiosensitivity test to better radiation therapy decisions for p
 

A molecular signature index technology that can lead to better radiation therapy decisions for patients with cancer is being developed into a reliable radiosensitivity test by CvergenX, Inc., an advanced cancer diagnostics company.

More...